title: [Effect of Chinese herbal medicine on patients with primary hepatic carcinoma in III stage during perioperational period: a report of 42 cases].
abstract: OBJECTIVE
  To investigate the synergetic effect of general therapy of Chinese herbal medicine with surgical operation.
  
  
  METHODS
  Fourty-two patients in the integrative group were treated with jiedu xiaozheng yin for 7 days before operation, and fuzheng yiliu recipe after operation for 2 years, and 30 patients in the control group underwent operation alone. Their cellular immune function, survival rate and recurrence rate were compared and analyzed.
  
  
  RESULTS
  The accumulative survival rate of 6-month, 12-month, 24-month and 36-month in the integrative group was 97.6%(41/42), 85.7%(36/42), 52.3% (22/42) and 45.5(17/42)% respectively and those in the control group 96.7% (29/30), 83.3% (25/30), 50.0% (15/30) and 30.0% (9/30), respectively, among them the 36-month survival rate was significantly different between the two groups (P < 0.05). The 24-month recurrence rate in the two groups was 54.8% and 80.0% respectively, the difference between the two was significant (P < 0.05).
  
  
  CONCLUSIONS
  Administration of compound Chinese herbal medicine in peri-operational period has definite effect on primary hepatic carcinoma in III stage, it can improve patients' immune function, decrease the recurrence rate and increase the cumulative survival rate.
authors.affiliation: Department of Oncology, The Second Provincial People' s Hospital of Fujian, Fuzhou. chenliwu05@21cn.com
authors.forename: Li-Wu
authors.initials: LW
authors.lastname: Chen
authors.forename: Jing
authors.initials: J
authors.lastname: Lin
authors.forename: Wen
authors.initials: W
authors.lastname: Chen
authors.forename: Weiping
authors.initials: W
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D015996:Survival Rate
chemical_list: D004365:Drugs, Chinese Herbal